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Introduction: Hereditary hyperekplexia is a neurological disorder characterized by excessive startle responses with
violent jerking to noise or touch, stiffening of the trunk and limbs, clenching of the fists and attacks of a
high-frequency trembling. Hyperekplexia has a heterogeneous genetic background with several identified causative
genes and demonstrates both dominant and recessive inheritance. Mutations in the glycine receptor alpha 1 subunit
gene occur in about 30 percent of hyperekplexia cases.
Case presentation: In this study, we report the case of a Hungarian boy whose abnormal movements, muscle
stiffness and convulsions were first noted when he was 4 days old. Neurological and electrophysiological
investigation suggested the clinical diagnosis of hyperekplexia.
Conclusions: Direct sequencing of the coding regions and the flanking introns of the glycine receptor alpha 1
subunit gene revealed a novel heterozygous missense mutation (c.211A/T, p.Ile71Phe). Genetic screening of our
patient’s family revealed that the clinically unaffected parents and sister do not carry the mutation, suggesting that
the identified sequence change is a de novo mutation. Since hyperekplexia can have severe consequences,
including sudden infant death due to laryngospasm and cardiorespiratory failure, identification of the causative
genetic alteration(s) of the disease is high priority. Such knowledge is necessary for prenatal diagnosis, which would
allow informed family planning and greater parental sensitivity to hyperekplexia 1-associated risks.
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Hereditary hyperekplexia (HKPX, ORPHA3197) is an
early-onset neurological disorder characterized by exces-
sive startle responses with violent jerking to sudden, un-
expected auditory or tactile stimuli [1,2]. Hyperekplexia
usually develops shortly after birth: neonates have pro-
longed periods of stiffness, clenching of the fists and at-
tacks of a high-frequency trembling [1,2]. Hyperekplexia
can have severe consequences such as sudden infant
death due to laryngospasm and cardiorespiratory failure
[1]. The symptoms tend to resolve after infancy; how-
ever, adults may have increased startle-induced falls or
nocturnal muscle jerks [1].* Correspondence: nikoletta.nagy@gmail.com
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unless otherwise stated.Hyperekplexia has a heterogeneous genetic background
[3,4]. Different mutations in several genes involved in gly-
cinergic neurotransmission can lead to hyperekplexia, and
the disease exhibits both autosomal recessive and domin-
ant inheritance [3,4]. Mutations in the glycine receptor
alpha 1 subunit gene (GLRA1) result in hyperekplexia 1
(OMIM149400) and occur in about 30 percent of hyper-
ekplexia 1 cases [5]. Mutations in other genes such as
the glycine receptor beta subunit gene (GLRB; HKPX2,
OMIM614619) [6], the glycine transporter solute carrier
family 6 member 5 gene (SLC6A5; HKPX3, OMIM614618)
[7], the glycine receptor locator gephyrin gene (GPHN;
OMIM603930) [8] and the postsynaptic glycine enhancer
collybistin gene (ARHGEF9; OMIM300429) have also been
associated with this clinical condition [9].
In this manuscript, we present the clinical and genetic
investigations of a Hungarian family affected by hyperek-
plexia 1 and the identification of a novel disease-causing
heterozygote missense mutation of the GLRA1 gene.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A male neonate was born to term at the 40th week of
gestation by cesarean section delivery after an uneventful
pregnancy. His birth weight was 3990g and Apgar score
was 9/10. At day 1 post-term, he developed a pneumo-
thorax and was admitted to the perinatal intensive care
unit for extra oxygen and parenteral fluid therapy. At day
4 post-term, abnormal movements, stiffness of the muscles
and convulsions were observed, and phenobarbital therapy
was initiated. A neurogical investigation described dyskin-
esia. At day 11 post-term, he was hospitalized in a develop-
mental neurology ward. An examination did not identify
any hypoxia-induced regulatory abnormalities. The ob-
served recurrent muscular hypertonia was attributed toFigure 1 Identification of a novel mutation in the GLRA1 gene and ge
patient (II/2) DNA revealed a novel heterozygous missense mutation in exo
(I/1, I/2 and II/1) carry only the wild-type sequence, suggesting a de novo m
the mutation (p.Ile71Phe) from different species indicates that the region is
that the identified sequence alteration is a de novo mutation.a suspected ion channel disorder and carbamazepine
therapy was initiated.
Ultrasonography of his hip indicated the possibility of
dysplasia on the left side, and ultrasonography of his ab-
domen revealed bilateral mild pyelectasis. The results of
neurosonography, electroencephalography and magnetic
resonance imaging of the head did not indicate any ab-
normalities of the central nervous system.
After pre-test genetic counseling was performed and
written informed consent was obtained from his parents, a
blood sample was taken from our patient, his clinically un-
affected sister and his clinically unaffected parents for gen-
etic investigation. Genomic deoxyribonucleic acid (DNA)
was isolated using a BioRobot® EZ1 DSP Workstationnetic screening of the affected family. (a) Direct sequencing of our
n 3 of the GLRA1 gene. (b) The clinically unaffected family members
utation. (c) Comparison of GLRA1 protein sequences in the region of
highly conserved. (d) Genetic analysis of the affected family suggests
Horváth et al. Journal of Medical Case Reports 2014, 8:233 Page 3 of 4
http://www.jmedicalcasereports.com/content/8/1/233(Qiagen; Hilden, Germany). The coding regions of the
GLRA1 gene and the flanking introns were amplified and
sequenced (using primer sequences obtained from the
UCSC Genome Browser, http://www.genome.ucsc.edu/).
A molecular genetic investigation was carried out by the
amplification and direct sequencing of the GLRA1 gene.
Having identified the putative causative mutation in our
patient (II/1), mutation screening of the unaffected family
members (I/1, I/2 and II/1) was carried out. Direct se-
quencing of the coding regions and the flanking introns of
the GLRA1 gene revealed a novel heterozygous missense
mutation (c.211A/T, p.Ile71Phe) in exon 3 (Figure 1a).
Mutation was confirmed by a second validation method,
re-sequencing. Genetic screening of the affected family
revealed that the clinically unaffected parents (I/1 and I/2)
and the unaffected sister (II/1) did not carry the mutation,
suggesting that the identified novel sequence alteration is
a de novo mutation in our patient (Figure 1d).
Conclusions
In this manuscript, we report the case of a Hungarian pa-
tient with hyperekplexia, a potentially fatal neurological
disorder characterized by pronounced startle responses.
Abnormal movements, stiffness and convulsions were first
noted in our patient at day 4 post-term, which correlates
well with the early onset of the disease.
Hyperekplexia has been linked to genetic alterations in
genes involved in an inhibitory neurotransmitter, glycine
neurotransmission [3,4]. Both compound heterozygous
patients and homozygous mutation carriers have been
described in the literature for recessive forms of the dis-
ease [10]. A heterozygous missense mutation (c.211A/T,
p.Ile71Phe) was detected in our patient in exon 3 of the
GLRA1 gene, establishing the diagnosis of hyperekplexia
1 and suggesting that the mutation is an autosomal
dominant form of the disease.
The GLRA1 gene encodes a neurotransmitter-gated ion
channel transmembrane protein with three transmembrane
segments (TM1-3) [11,12]. Binding of glycine to its re-
ceptor increases the chloride conductance, produces hyper-
polarization and, thus, the inhibition of neuronal firing
[11,12]. Previous studies have attributed dominant forms of
hyperekplexia 1 to mutations within the pore-lining trans-
membrane segment (TM2) and adjacent regions, recessive
forms to mutations within the other transmembrane seg-
ments (TM1 and TM3), and the null allele of the GLRA1
gene to the deletion of exons 1-7 [11,12]. The novel hete-
rozygous missense mutation (p.Ile71Phe) reported here is
located close to the NH2-terminal of the GLRA1 protein
outside the transmembrane segments (Figure 1b), in a
highly conserved region (Figure 1c). Other missense muta-
tions have been detected in this region in patients with
hyperekplexia 1 (p.Trp68Cys and p.Arg72His) [3], and in
spasmodic mice (p.Ala52Ser) [13]. The functional analysisperformed on the spasmodic mouse model suggested that
the p.Ala52Ser missense mutation results in reduced gly-
cine sensitivity [13]. Recessive mutations in the N-terminal
regions or majority of recessive hyperekplexia mutations
have trafficking defects [14,15]. Dominant mutations can
cause reduced glycine sensitivity [14,15]. Based on these
previous studies, we hypothesize that the reported novel
missense mutation detected in our Hungarian patient
might lead to reduced glycine sensitivity as well. It is also
interesting to note that previously reported missense mu-
tations in this region (human p.Trp68Cys and p.Arg72His
and murine p.Ala52Ser) are all associated with the reces-
sive form of hyperekplexia 1, indicating the possibility that
other undetected mutations might contribute to the clin-
ical symptoms of our Hungarian patient.
Our patient’s clinically unaffected family members were
also screened and shown to carry only wild-type sequence
of the GLRA1 gene. Our results suggest that this novel
missense sequence change (c.211A/T, p.Ile71Phe) identi-
fied in the index patient is a de novo mutation.
The consequences of the hyperekplexia 1 can be se-
vere, warranting further efforts to elucidate the nature of
the disease despite the complications implicit with the
heterogenic genetic background. With the identification
of the underlying genetic abnormalities, prenatal screen-
ing is available for affected families and allows informed
family planning. In the future, knowledge of the genetic
causes of this life-threatening disease may also contrib-
ute to the development of novel therapeutic alternatives.
Consent
Written informed consent was obtained from the patient’s
parents for publication of this case report and any accom-
panying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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